Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.


  • Dec 21, 2010 Joint Development of Therapeutic Cancer Vaccine WT4869
    [PDF 73KB]
  • Nov 29, 2010 Organizational Restructuring and Personnel Changes
    [PDF 176KB]
  • Oct 26, 2010 Chronic Hepatitis C Treatment, Pegasys®, and Antiviral Drug, Copegus®,
    Filed for Additional Indication of Compensated Liver Cirrhosis Related to Hepatitis C
    [PDF 137KB]
  • Oct 25, 2010 Personnel Changes
    [PDF 168KB]
  • Oct 22, 2010 Revision of Financial Outlook for Fiscal Year 2010
    (January 1 - December 31, 2010)
    [PDF 43KB]
  • Oct 20, 2010 Relief Efforts Support for the Serious Flood Disaster Area in Pakistan
    [PDF 122KB]
  • Oct 19, 2010 Data Presented at the American Society for Bone and Mineral Research
    on Japanese Phase III Study of 'Eldecalcitol,' an Active Vitamin D3 Derivative
    [PDF 169KB]
  • Oct 18, 2010 ACTEMRA/RoACTEMRA (tocilizumab) supplemental marketing authorizations submitted in the US and Europe for the treatment of systemic Juvenile Idiopathic Arthritis
    - New hope for children suffering from debilitating arthritis -
    [PDF 260KB]
  • Oct 18, 2010 Chugai’s Novel Antibody Engineering Technology Published in Nature Biotechnology
    - Enabling single antibody molecule to block the function of target antigen multiple times -
    [PDF 333KB]
  • Oct 15, 2010 Introduction of a Personnel Program to Provide Contract Workers with Opportunities to Change to Full Employment
    - To further promote motivated human resources -
    [PDF 171KB]
  • Oct 14, 2010 F. Hoffmann-La Roche Announces Third Quarter Sales 2010
    [PDF 21KB]
  • Oct 14, 2010 Supply Plan of "Tamiflu®" Anti-influenza Drug
    [PDF 171KB]
  • Oct 07, 2010 Contribution of Para-transit Vehicles to Welfare Services
    [PDF 219KB]
  • Oct 04, 2010 Chugai Presents an Anti-Cancer Charity “Medicine and Humor”
    [PDF 199KB]
  • Sep 28, 2010 Information about Plan to Appoint a New Accounting Auditor
    [PDF 83KB]
  • Sep 09, 2010 Trial Use of Electric Vehicles - Enhancement of Preventive Measures Against Global Warming -
    [PDF 189KB]
  • Sep 08, 2010 Anti-Angiogenic Anti-Cancer Agent Avastin® Condition for Approval (All Patients Surveillance) Removed in Japan
    [PDF 178KB]
  • Sep 02, 2010 Anti-Cancer Agent, Xeloda® Filed for Advanced or Refractory Gastric Cancer By “New Drug Application Based on Evidence in the Public Domain”
    [PDF 168KB]
  • Sep 01, 2010 Renewal of “Cancer Information Guide,” a Website for Patients: - Maximizing Convenience through Unique Built-in Search Engine -
    [PDF 157KB]
  • Aug 30, 2010 Awareness Enhancement of Colon Diseases with Display of Giant-Sized Balloon Art, "Japanese Version of a Giant Colon"
    - "Relay for Life Japan 2010" -
    [PDF 260KB]
  • Aug 06, 2010 Organizational Restructuring and Personnel Changes
    [PDF 139KB]
  • Aug 04, 2010 "ACTEMRA®" Humanized Anti-Human IL-6 Receptor Monoclonal Antibody Conditions for Approval (All Patients Surveillance) Lifted in Japan
    [PDF 196KB]
  • Jul 30, 2010 Assisting Work-Life Balance
    [PDF 201KB]
  • Jul 28, 2010 New Interactive Videos at Permanent Exhibit "Dr. Kitanomaru's Bio Pharmaceutical Laboratory" at the Science Museum
    [PDF 234KB]
  • Jul 22, 2010 F. Hoffmann-La Roche Announces 2010 Half Year Results
    [PDF 13KB]
  • Jul 12, 2010 Support for Areas Affected by Foot-and-Mouth Disease in Miyazaki Prefecture
    [PDF 131KB]
  • Jun 21, 2010 Anti-Cancer Agent, Herceptin® Designated for Priority Review by Ministry of Health, Labour and Welfare
    [PDF 194KB]
  • Jun 18, 2010 Recombinant Human Erythropoietin,“EPOGIN® Subcutaneous Injection Syringe 24000,” Approved in Japan
    [PDF 187KB]
  • Jun 18, 2010 RoACTEMRA: New Hope for Children with Systemic Juvenile Idiopathic Arthritis
    [PDF 275KB]
  • Jun 14, 2010 “Transformation in Medical Care & Rheumatoid Arthritis” Chugai Holds an Educational Event at Yurakucho Mullion, Tokyo
    [PDF 163KB]
  • Jun 09, 2010 New Licence Extension for RoACTEMRA in Europe
    [PDF 186KB]
  • May 11, 2010 Determination of Terms and Conditions of Stock Options (Stock Acquisition Rights)
    [PDF 84KB]
  • Apr 26, 2010 RoACTEMRA Recommended for Approval in Europe for the Reduction of Joint Damage and Improvement in Physical Function in Rheumatoid Arthritis
    [PDF 200KB]
  • Apr 23, 2010 Issuance of Stock Options (Stock Acquisition Rights)
    [PDF 78KB]
  • Apr 15, 2010 F. Hoffmann-La Roche Announces First Quarter Sales 2010
    [PDF 64KB]
  • Mar 19, 2010 Anti-Cancer Agents, Herceptin® and Xeloda® Filed for HER2-positive Advanced or Recurrent Gastric Cancer
    [PDF 180KB]
  • Mar 17, 2010 ACTEMRA(tocilizumab) filed in the US for Prevention of Structural Joint Damage and Improvement of Physical Function in Rheumatoid Arthritis
    [PDF 180KB]
  • Feb 19, 2010 Chugai to In-license Hedgehog Pathway Inhibitor “RG3616”
    [PDF 177KB]
  • Feb 04, 2010 Personnel Changes
    [PDF 177KB]
  • Feb 03, 2010 F. Hoffmann-La Roche Announces Financial Results for Fiscal 2009
    [PDF 72KB]
  • Feb 03, 2010 Notice Regarding Dividend and the Difference between Dividend Forecast
    [PDF 40KB]
  • Feb 03, 2010 Appointments of Directors
    [PDF 17KB]
  • Jan 22, 2010 Relief Efforts Support for the Devastating Big Earthquake Disaster Area in Republic of Haiti
    [PDF 123KB]
  • Jan 12, 2010 Chugai Renews its Website for the First Time in Six Years
    [PDF 359KB]
  • Jan 09, 2010 ACTEMRA®,a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody,Approved in the United States for Rheumatoid Arthritis
    [PDF 118KB]
  • Like
  • Tweet
  • LINE it!
  • E-mail
Back to top